Varian Medical Systems, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $23.9M | 429 | 60.0% |
| Consulting Fee | $9.8M | 596 | 24.7% |
| Royalty or License | $2.3M | 33 | 5.7% |
| Gift | $1.3M | 79 | 3.3% |
| Travel and Lodging | $831,506 | 1,423 | 2.1% |
| Education | $661,777 | 77 | 1.7% |
| Honoraria | $364,536 | 144 | 0.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $282,582 | 129 | 0.7% |
| Food and Beverage | $243,634 | 4,910 | 0.6% |
| Long term medical supply or device loan | $91,591 | 2 | 0.2% |
| Grant | $24,500 | 5 | 0.1% |
| Debt forgiveness | $15,593 | 3 | 0.0% |
| Charitable Contribution | $15,000 | 3 | 0.0% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| MRA FLASH Multi-Investigator | $3.1M | 0 | 16 |
| Strategic Collaboration Agreement - MD Anderson | $2.0M | 0 | 1 |
| RPA for Radiation Therapy - MD Anderson | $1.5M | 0 | 7 |
| MRA with U. Penn | $1.2M | 0 | 28 |
| MRA with U Michigan | $955,169 | 0 | 18 |
| MRA with MD Anderson Cancer Center | $892,457 | 0 | 10 |
| MRA with WU | $774,323 | 0 | 11 |
| MRA with BWH | $601,941 | 0 | 16 |
| MRA with UCLA | $519,984 | 0 | 7 |
| Phase II trial of SRT to induce SDR- UT | $515,800 | 0 | 7 |
| Phase III Study of SR versus SAbR- UTSW | $510,000 | 0 | 3 |
| MRA with Duke University | $471,708 | 0 | 9 |
| Master Research Agreement Henry Ford | $443,700 | 0 | 7 |
| MRA with Henry Ford | $425,000 | 0 | 4 |
| TGF-b with UCSF | $420,240 | 0 | 9 |
| Non-Coplanar SBRT with HyperArc - UCLA | $413,438 | 0 | 4 |
| MeDomics, AI Framework - UCSF | $384,977 | 0 | 3 |
| 3D patient surface modeling- UofA | $341,300 | 0 | 18 |
| Thalamotomy Study - UAB | $318,696 | 0 | 5 |
| Radiotherapy and Immunotherapy for metastatic Cancer-Leland | $250,000 | 0 | 2 |
| Health outcomes and cost analysis of surgery-SCRI | $246,768 | 0 | 26 |
| Analysis of AR and outcome of RO SRS and SBRT-HF | $225,000 | 0 | 2 |
| MRA with Stanford | $222,014 | 0 | 8 |
| Fresolimumab and SAR - Stanford (Genzyme) | $216,667 | 0 | 4 |
| RFADigital Symptom Tracking | $210,539 | 0 | 3 |
| MRCECT for treatment planning and target localization in abdominal radiation therapy - Montefiore | $198,328 | 0 | 4 |
| Development of proton modulated arc therapy as the means to biologically optomize proton radiotherapy with UPenn | $192,627 | 0 | 4 |
| Single Arm Study of SABR Lung Cancer | $188,000 | 0 | 2 |
| Auto-Segmentation - Cone Health | $187,986 | 0 | 3 |
| Whole-brain radiation versus stereotactic | $180,000 | 0 | 3 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2021 |
|---|---|---|---|---|
| Jeffery Balser, Md, MD | Anesthesiology | Nashville, TN | $849,330 | $0 |
| Phillip Febbo, M.d, M.D | Hematology & Oncology | Durham, NC | $567,631 | $0 |
| Dr. Clifford Robinson, Md, MD | Radiation Oncology | Saint Louis, MO | $466,722 | $0 |
| Unknown Provider | — | — | $223,014 | $0 |
| Dr. Ian Crocker, Md, MD | Radiation Oncology | Atlanta, GA | $189,176 | $0 |
| John Kresl, Md, Ph.d, MD, PH.D | Diagnostic Radiology | Phoenix, AZ | $116,802 | $0 |
| Unknown Provider | — | — | $97,552 | $0 |
| Dr. Haroutioun Shahinian, M.d, M.D | Hematology & Oncology | El Paso, TX | $87,182 | $0 |
| Joe Chang, M.d., Phd, M.D., PHD | Radiation Oncology | Houston, TX | $59,638 | $0 |
| Charles Simone, Md, MD | Radiation Oncology | New York, NY | $59,396 | $0 |
| Dr. Farzan Siddiqui, M.d., Ph.d, M.D., PH.D | Radiation Oncology | Detroit, MI | $53,238 | $0 |
| Gordon Wong, M.d, M.D | Radiation Oncology | Los Gatos, CA | $49,539 | $0 |
| Unknown Provider | — | — | $48,500 | $0 |
| Dr. M. Salim Siddiqui, M.d., Ph.d, M.D., PH.D | Radiation Oncology | Detroit, MI | $47,564 | $0 |
| Dr. John Adler, Md, MD | Neurological Surgery | Stanford, CA | $45,064 | $0 |
| Drexell Boggs, M.d, M.D | Radiation Oncology | Birmingham, AL | $39,475 | $0 |
| Markus Bredel, Md Phd, MD PHD | Radiation Oncology | Miami, FL | $38,935 | $0 |
| Amar Kishan, M.d, M.D | Radiation Oncology | Los Angeles, CA | $37,204 | $0 |
| Dr. Brian Czito, M.d, M.D | Radiation Oncology | Durham, NC | $32,717 | $0 |
| Michelle Alonso-Basanta, Md, MD | Radiation Oncology | Philadelphia, PA | $31,206 | $0 |
| Natia Esiashvili, Md, MD | Radiation Oncology | Atlanta, GA | $30,226 | $0 |
| Rakesh Patel, Md, MD | Radiation Oncology | Los Gatos, CA | $29,477 | $0 |
| Drew Moghanaki, Md, MD | Radiation Oncology | Los Angeles, CA | $27,869 | $0 |
| Dr. Daniel Schiffner, M.d, M.D | Radiation Oncology | Palo Alto, CA | $25,930 | $0 |
| Dr. Marco Amendola, Md, MD | Body Imaging | Miami, FL | $25,701 | $0 |
Top Products
- OTHER $9.9M
- Eclipse $5.3M
Associated Products (17)
- OTHER $10.0M
- TrueBeam $6.5M
- Eclipse $5.3M
- Proton System $2.4M
- Halcyon $1.8M
- Edge $1.7M
- Radiation Oncology $1.6M
- Clinac $525,151
- ProBeam $451,601
- Linac $443,295
- RapidPlan $226,048
- Calypso $208,494
- Treatment Planning Systems $75,229
- BrachyVision $69,406
- Calypso System $60,847
- Brachy Products $38,624
- Rapid Arc $10,646
Payment Categories
- Food & Beverage $243,634
- Consulting $9.8M
- Travel & Lodging $831,506
- Research $23.9M
- Royalties $2.3M
About Varian Medical Systems, Inc.
Varian Medical Systems, Inc. has made $39.8M in payments to 2,258 healthcare providers, recorded across 7,833 transactions in the CMS Open Payments database. In 2021, the company paid $3.9M. The top product by payment volume is OTHER ($9.9M).
Payments were distributed across 76 medical specialties. The top specialty by payment amount is Radiation Oncology ($2.4M to 1,298 doctors).
Payment categories include: Food & Beverage ($243,634), Consulting ($9.8M), Research ($23.9M), Travel & Lodging ($831,506), Royalties ($2.3M).
Varian Medical Systems, Inc. is associated with 17 products in the CMS Open Payments database, including OTHER, TrueBeam, and Eclipse.